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Abstract
Aim: Inhibitors of mammalian efflux pumps are known to potentiate 
antibiotic susceptibility in bacteria by inhibiting bacterial efflux pumps 
as well. In this study the effect of 2nd generation mammalian efflux 
pump inhibitor valspodar (PSC833) on inhibition of efflux pumps in 
bacteria is tested. 
Methods: Disc diffusion assay for several antimicrobial agents such as 
cefoxitine, oxacillin, gentamicin, ticarcillin-clavulanate norfloxacin and 
ofloxacin was performed in the presence and absence of PSC 833 in 
culture media of Gram positive and Gram negative bacteria and zones 
of inhibition were compared. Accumulation of the universal efflux 
pump substrate ethidium bromide in test organisms was measured in 
the presence and absence of PSC 833. 
Results: PSC833 at concentrations starting from 62.5 µg/ml downwards 
till 3.12 µg/ml have significantly improved and restored the sensitivity 
of S.aureus and MRSA towards all tested antibiotics and resulted in 
highest accumulation of ethidium bromide within the cells, when 
compared to the other mammalian efflux inhibitors, verapamil and 
reserpine. However no effect was observed on the Gram negative P. 
aeruginosa and vancomycin resistant Enterococci (VRE). 
Conclusions: The results of this study indicate that PSC 833 represents 
a good candidate for use in combination with examined antibiotics to 
restore their clinical efficacy. 
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Introduction
Shortage of antibiotics in the treatment of mul-
tiple drug resistant (MDR) bacterial infections has 
necessitated the search for novel antibiotics or im-
provement of the existing ones. Improving the ef-
ficacy of the available antibiotics would certainly be 
a more reasonable alternative especially when these 
antibiotics have been extensively investigated and 
used by patients. One way to improve effective-
ness would be by combining the antibiotic with a 
resistance mechanism inhibitor as in ampicillin/ sul-
bactam in which sulbactam acts as a ß-lactamase 
inhibitor[1]. Efflux of antimicrobials by specific and 
nonspecific pumps is a multidrug resistance mech-
anism in bacteria. Inhibition of efflux renders the 
bacteria more susceptible to variable antimicrobials 
that happens to be substrates to these pumps. Thus 
the search for efflux inhibitors has been intriguing 
for scientists. Mammalian efflux pump inhibitors 
are used to overcome mammalian cells resistance 
to cancer drugs. Resemblance has been shown be-
tween the efflux pumps used by the mammalian 
cells and some efflux pumps in bacteria [2]. Clini-
cally used mammalian efflux pump inhibitors (MEPI) 
are more encouraging to use when compared with 
non-mammalian inhibitors such as CCCP or reser-
pine that are known to have high toxicity in man 
[3]. Mullin et al (2004) demonstrated the usefulness 
of the mammalian efflux pump inhibitors biricodar 
(VX-710) and timcodar (VX-853) and tariquidarin in 
potentiating antibiotic susceptibility in Gram posi-
tive bacteria[4]. The effect was detected by either 
the increased intracellular concentration of labeled 
ciprofloxacin, or by the increased intracellular ac-
cumulation of the universal efflux pump substrate 
ethidium bromide after exposure of these bacteria 
to the efflux inhibitors [4]. Such results were prom-
ising for the development of new antibiotics com-
bination. Antibiotic resistance in S. aureus involves 
several mechanisms: Methicillin resistance for exam-
ple involves the synthesis of an alternative penicillin 
binding protein (PBP-2a) that is coded for by the 
mecA gene, aminoglycoside resistance is mediated 
by aminoglycoside modifying enzymes, ribosomal 
mutations, and active  efflux. An array of efflux 
pumps were detected in S.aureus and methicillin 
resistant S. aureus, Both the efflux pumps NorB and 
NorC confer resistance to quinolones, such as cip-
rofloxacin, norfloxacin and sparfloxacin [5,6]. norA 
gene efflux proteins were thought to specifically 
efflux the norfloxacin, but subsequently was found 
to confer resistance to a number of antimicrobi-
als, including chloramphenicol [7, 8]. Of the natural 
efflux inhibitors that has been shown to have an 
inhibitory effect on NorA efflux pumps in S.aureus 
is reserpine [9]. Reserpine is a plant indole alkaloid 
that is known for its ability to inhibit activation of 
the efflux of cancer drugs outside the cells, however 
numerous side effects within its therapeutic range 
(0.1 to 0.25 mg) has been documented [10]. Vera-
pamil on the other hand is a synthetic hypertension 
drug and a 1st generation MEPI, this drug has been 
used as an inhibitor of the bacterial p-glycoprotein 
(p-gp) efflux pump [11]. Like verapamil, Valspodar 
(PSC833) a mammalian p-gp efflux pumps inhibitor 
that is clinically used to restore the activity of some 
drugs in drug-resistant tumor cells[12]. PSC833 
however is a 2nd generation p-gp pump inhibitor 
that is selective and less toxic than the first genera-
tion agents. PSC-833 is a non-immunosuppressive 
cyclosporine derivative that potently and specifically 
inhibits P-gp. In vitro experiments indicate that PSC-
833 interacts directly with p-gp with high affinity 
and probably interferes with the ATPase activity of 
p-gp. Studies in multidrug resistant tumour models 
confirm P-gp as the in vivo target of PSC-833 and 
demonstrate the ability of PSC-833 to reverse MDR 
leukaemias and solid tumours in mice [13]. To our 
knowledge PSC833 has not been investigated as 
a bacterial efflux pump inhibitor. The aim of this 
study is to evaluate the activity of PSC833 in bacte-
ria through its ability to potentiate antibiotic activity 
and inhibiting efflux pumps. 
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Experimental
Compounds: antibiotics, chemicals and 
growth media
Valspodar (PSC833) was obtained from Tocris® 
(UK). A fresh stock solution of PSC833 was pre-
pared by dissolving in dimethyl-sulfoxide (DMSO) to 
give a final concentration of 1mg/ml. Stock solu-
tions of Verapamil and reserpine (Sigma® Aldrich) 
were prepared by dissolving the former in distilled 
water to give a final concentration of 5mg/ml, and 
the latter in dimethyl-sulfoxide( DMSO) to give a 
final concentration of 0.02mg/ml. Dilutions were 
prepared in sterile distilled water. The following an-
tibiotic discs were obtained from Oxoid® (Germany), 
Oxacillin (1µg/ml), norfloxacin (10µg/ml), gentamicin 
(10 µg/ml), ofloxacin (5 µg/ml), ticarcillin clavulanic 
acid(85 µg/ml), and cefoxitin (30 µg/ml).All chemi-
cals and antibiotics were kept in cold, dark place 
(refrigerator). Mueller Hinton Agar (MHA) and broth 
(MHB) were obtained from Himedia (India).
Bacterial strains
The study was conducted on Staphylococcus au-
reus ATCC 6538, Pseudomonas aeruginosa ATCC 
9027. Clinical strains: Methicillin resistant Staphylo-
coccus aureus (MRSA), MDR Pseudomonas aerugi-
nosa, and vancomycin resistant Enterococcus (VRE) 
obtained from king Hussein Cancer Center (KHCC). 
All bacterial strains were verified and identified at 
the source, and were maintained by sub culturing 
into fresh nutrient agar and Tryptic soy agar (Hime-
dia, India) every 2 weeks. Cultures were also pre-
served in 10% glycerol at –70° C until required for 
use. 
Determination of Minimal Effective 
Concentration (MEC) of PSC 833
Varying concentrations of the PSC 833 starting 
from 250µg /ml down to 3.12µg /ml in 0.5ml of MHB 
were prepared. An aliquot of 50µl of S. aureus or 
MRSA18-24hrs culture adjusted to contain 105CFU/
ml was added to all tubes[14]. Negative control 
tubes contained only 0.5 ml of MHB, and the test 
organism. Test tubes were incubated at 37° C for 
15 and 30 min[14]. After 15 minutes sterile swabs 
were used to transfer from each tube to the surface 
of a fresh MHA plate. Inoculums were allowed to 
dry and antibiotic discs were applied on the plates. 
Plates were incubated at 37°C overnight. Diameter 
of zone of inhibition was measured in mm. Experi-
ment was repeated 3 times. Results are the average 
readings of three separate experiments according to 
the recommendation of CLSI [15].
Kinetic study 
To identify the time required for PSC 833 to ex-
ert its best effect as measured by the diameter of 
the zone of inhibition of antibiotics, PSC 833 was 
added at a concentration of 62.5 µg/ml to bacte-
rial culture containing 105CFU/ml. Inoculums were 
cultured every 10 minutes on fresh MHA starting 
from 0 time which is upon the immediate addi-
tion of PSC833 to the media (nullifying the carry 
over effect) Antibiotic discs were applied. Bacterial 
controls in absence of PSC833 were also included. 
Plates were incubated at 37°C overnight. Diameter 
of the zones of inhibition were measured in mm. 
Readings presented are the results of the average 
of three experiments.
Detecting changes in MIC using E-Test
E-Test (Oxoid) was performed according to manu-
facturer’s instructions. Briefly, inoculums of an over-
night culture of S.aureus and MRSA were adjusted 
to 0.1 O.D at 625nm corresponding to 106 CFU /ml. 
An aliquot of PSC 833 was added to 1 ml of MHB 
to give a concentration of 62.5 µg/ml. An aliquot 
of the test culture (0.5 McFarland), was added to 
the mixture to get a final concentration of 105 CFU/
ml tubes were then incubated for 30 min. Bacterial 
culture from the tube was swabbed on the plate 
and allowed to dry. Oxacillin E-strip was applied. 
As specified by the manufacturer’s instructions the 
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detected MIC corresponded to the concentration of 
the antibiotic where growth of the test organism 
touched the sides of the strip
Ethidium bromide accumulation assay
Ethidium bromide efflux was determined as pre-
viously described [14]. Briefly S.aureus  and MRSA 
were grown overnight in nutrient broth. Bacterial 
suspensions (O.D of 0.2 at 550 nm) were prepared 
in uptake buffer (110 mM NaCl, 7 mM KCl, 50 mM 
NH4Cl, 0.4 mM Na2HPO4, 52 mM Tris base and 
0.2% glucose, adjusted to pH 7.5 with HCl). Sus-
pensions were exposed to 2 mg/L ethidium bromide 
in the presence of different efflux pump inhibitors 
(EPIs) for 30 min at 37°C. The cells were pelleted 
down by centrifugation and resuspended in fresh 
buffer. Fluorescence was recorded every 5 minutes 
at an excitation wavelength of 530 nm and an emis-
sion wavelength of 600 nm in a spectroflorometer 
(Promega Glomax®) for a period of 30 minutes 
starting immediately (0 time). Readings were com-
pared to controls exposed to ethidium bromide for 
the same time period in the absence of any efflux 
inhibitor. Results plotted are the average of three 
readings on different sets of experiments.
Results 
Minimum effective concentration of PSC 
833 (MEC)
The exposure of both MRSA and S.aureus to 
descending concentrations of PSC833 resulted in a 
significant increase in the diameter of zone of in-
hibition of all antibiotics used (Table 1). However 
comparing the percentage increase in the diameter 
Table 1.  Determination of the minimal effective concentration of valspodar (PSC338) as a function of 
diameter of zone of inhibition in mm.
Antibiotic
Bacteria Diameter of Zone of inhibition mm (% increase in Zone of inhibition
R·  I* S Control PSC338 concentration (µg/ml)
250 125 62.5 50 31.25 25 12.5 6.25 3.12
























































































































































































































*CLSI breakpoints for antibiotics: R: resistant, I: intermediate sensitivity, S: sensitive.
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of the zone of inhibition for each antibiotic at each 
PSC833 concentration used relative to the concen-
tration of the antibiotic on the disc have led us to 
conclude that the MEC was variable according to 
the antibiotic but a concentration of 50ug/ml was 
found potentiating for the activity of all antibiotics.
Time dependent effect of valspodar (PSC 
833) on MRSA and S. aureus antibiotic 
susceptibility.
A relatively high concentration of PSC833 (62.5 
µg/ml) was chosen to maximize the chance of ob-
serving an effect in combination with antibiotics 
against isolates with multiple resistance mecha-
nisms. Kinetic studies using disc diffusion technique 
showed that after 10 minutes exposure there was a 
significant ≥2 fold increase (P< 0.05 (Mann Whitney 
test/SPSS)) in the zone of inhibition of all antibiot-
ics except for ticarcillin. Susceptibility to ticarcillin 
improved after 20 min by 1.6 fold for S.aureus and 
almost 3 folds on MRSA (Table 2). Immediate con-
tact with PSC833 (0 time) didn’t show significant 
increase in the zone of inhibition (Table 2) indicat-
ing that exposure time is required.
Changes in minimal inhibitory 
concentration of Oxacillin as detected by 
E test 
Oxacillin E-test was performed to detect the 
changes in MIC in both MRSA and S.aureus. Expo-
sure of S.aureus and MRSA for 30 min. significantly 
reduced the MIC of Oxacillin (Table 3).
Comparing the effect of PSC833 to other 
MEPIs on S.aureus and MRSA.
Effect of PSC 833 on improving antibiotic sen-
sitivity towards S.aureus and MRSA was compared 
to two known mammalian efflux pump inhibitors 
Verapamil and reserpine. PSC833 effect on improv-
Table 2. Effect of exposure time on valspodar (PSC 833) activity. 
Antibiotic Bacteria Control Diameter of Zone of inhibition mm
Time in minutes
0 10 20 30 40 50 60
Gentamycin S.aureus 15 38 30.3 30.3 30.3 36 34.6
MRSA 10 35.6 30.3 30 30 34 33.3
Oxacillin S.aureus 15 30 30.3 30 30 30 30
MRSA 6 18 16.3 18.6 14.6 22.6 22.6
Ticarcillin S.aureus 25 30 40 30 24.3 29 40
MRSA 6 16 18.3 19 15 20 20.6
Ofloxacin S.aureus 15 32 32 31.6 30.33 32 30.3
MRSA 13 32 31.6 31.6 31.3 30 30
Norfloxacin S.aureus 15 35 34.3 33.3 30.3 30 34.6
MRSA 13 30 30 30.3 29.6 30 31.3
Table 3.  Changes in MIC of Oxacillin in both 
S. aureus and MRSA upon exposure to 




% decrease in MIC
control PSC 833
S. aureus 0.06 0.015 75%
MRSA 2 0.012 99.25%
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ing antibiotic susceptibility as detected by increase 
in diameter of zone of inhibition was significantly 
(p < 0.05) superior to that of reserpine on both S. 
aureus and MRSA. However incomparable effect 
was observed between both Verapamil and PSC833 
(Table 4). Reserpine on the other hand potentiated 
the activity of the floroquinolones (ofloxacin, nor-
floxacin) and gentamycin in MRSA.
Other bacterial strains
No observed effect of PSC 833 under the same 
conditions in both MDR P. aeruginosa, and van-
comycin resistant enterococci and within the same 
range of antibiotics used.
Ethidium bromide accumulation assay
The ability of PSC833 to inhibit the efflux of 
ethidium bromide was evaluated through measur-
ing level of accumulation of this substrate within 
S.aureus and MRSA in the presence and absence of 
PSC833. The accumulation of EtBr in cells exposed to 
PSC833 for 30 min was significantly higher (P<0.05) 
than accumulation in cells not exposed to the MEPI 
(Figure 1A, 1B). The same result was observed with 
verapamil and the combination of both verapamil 
and PSC833. Reserpine on the other hand was sig-
nificantly less efficient in inhibiting efflux of EtBr in 
comparison to PSC833 (p < 0.05) in both S. aureus 
and MRSA. In fact the exposure of S. aureus to reser-
pine resulted in almost the same accumulation levels 
to that of controls (Figure 1B). Over a period of 30 
minutes there were no observed loss of fluorescence 
in the MEPI treated cells (Figure 2A, 2B) .
Discussion
Multi drug resistance in bacteria is identified by 
either a reduced diameter of zone of inhibition in 
the disc diffusion assays or increased MIC towards a 
group of unrelated antibiotics. In this study a signifi-
cant increase was observed in the diameter of zone 
of inhibition of the used antibiotics upon exposure 
of test strains to PSC833. 
Although it is well established that ß-lactam-
resistance in S. aureus is mediated by ß-lactamase 
Table 4.  Comparison between effect of valspodar (PSC338) and other efflux inhibitors on S. aureus and 
MRSA sensitivities to antibiotics.
Antibiotic Bacterial strain
Zone of inhibition (mm)
Control* valspodar 62.5µg/ml verapamil 200µg/ml Reserpine 2µg/ml
Gentamycin S.aureus 20 34.6 34 27.3
MRSA 13 32 36 27.3
Oxacillin S.aureus 21 30 30.3 15
MRSA 6 26 29 6
Ticarcillin/clav S.aureus 30 38 38 25
MRSA 6 31 27 6
Ofloxacin S.aureus 28 30 30 21
MRSA 13 30 28 21
Norfloxacin S.aureus 28 31 31 26.3
MRSA 13 30.6 32.6 26.3
Cefoxitine S.aureus 28 35.6 35.6 20
MRSA 10 28.6 32 10
*Controls are MEPI unexposed cells.
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Figure 1. Accumulation of EtBr in S. aureus (A) and MRSA (B) after 30 minutes exposure to PSC833 (62.5 µg/ml) or verapamil  
(200 µg/ml) or Reserpine at (2 µg/ml). 
Figure 2. Accumulation of EtBr in S. aureus (A) and MRSA (B) after exposure to MEPIs over a period of 30 min. S. aureus cells were 
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and/or the expression of penicillin-binding protein 
2a (PBP 2a) [16], the exposure of S.aureus and the 
clinical multi drug resistant MRSA strain to the MEPI 
(PSC833) improved their susceptibility to all ß-lac-
tams used with the complete restoration of activity 
for both oxacillin and cefoxitin. However this effect 
was relatively less prominent on floroquinolones 
activity on MRSA. Improvement of the activity of 
the versatile antibiotics used in this study after ex-
posure to PSC833, indicates that these antibiotics 
could be substrates of a nonspecific efflux pump 
or that PSC833 is affecting more than one efflux 
pump. Cefoxitin, gentamicin and floroquinolones are 
known to be substrates of different efflux pumps 
such as Lmr and NorA in S.aureus strains [14,17]. 
Reserpine is known to be an inhibitor of NorA pump 
in S.aureus and MRSA [14]. Reserpine significantly 
had better influence in improving susceptibility of 
MRSA towards floroquinolones compared to its ef-
fect on susceptibility towards ticarcillin and oxacillin. 
A comparison between reserpine and PSC833 (that 
potentiated the activity of all types of antibiotics) 
implies that the PSC 833 could actually be inhibiting 
more than one specific pump. 
Efflux pump inhibitors are known to have vari-
able effective concentrations depending on type of 
antibiotic and on the microbial strain [14,18 ], which 
explains the activity of PSC833 on S. aureus strains 
and not on other bacteria used in this study, moreo-
ver, MRSA strain was more affected by PSC833 than 
S. aureus. Clinical strains are known to express many 
different resistance mechanisms including multiple 
target-based mutations in addition to efflux mu-
tations [4]. Thus novel, induced or overexpressed 
pumps in MRSA could be involved.
Minimal effective concentrations of PSC833 var-
ied between various antibiotics used and with some 
antibiotics the MEC that resulted in ≥ two fold in-
crease in diameter of zone of inhibition was as low 
as 3.12 µg/ml. allowing concentration flexibility in 
combination with antibiotic, thus avoiding side ef-
fects (Table 1).
Ethidium bromide is a known universal substrate 
for efflux pumps in bacteria[19]. This substrate when 
inside the cell intercalates with cellular DNA result-
ing in a detectable fluorescence if subjected to UV 
light. The increased accumulation of EtBr after 30 
minutes exposure to PSC833 compared to that of 
the PSC833 unexposed cells (Figure 1A, 1B) sub-
stantiates the role of efflux pumps in resistance in 
these strains.
Recently Costa et al (2013) reviewed the efflux 
mechanisms of resistance in S. aureus and MRSA[20]. 
The authors have shown that most of the pumps in 
these organisms are energized by H+: drug antiport 
mechanism and that none of the reported efflux 
pumps in S. aureus or MRSA have ß-lactam antibi-
otics in their substrate collection. However, Truong-
Bolduc Q. (2007) reported the presence of an ABC 
transporter designated AbcA pump in MRSA that 
extrudes hydrophobic ß-lactams such as nafcillin, 
penicillin, methicillin and cefotaxime [21], which 
explains involvement of efflux pumps in ß-lactam 
resistance in S. aureus and MRSA. Such pump or a 
similar one could explain the observed results in this 
study. Alternatively, PSC833 could simply be bind-
ing to the transporter protein thus inhibiting drug 
transport rather than dissipating energy [14]. 
Comparative studies between PSC833 and other 
MEPI using the same experiments and the same 
conditions have shown similarity in effect between 
PSC833 and verapamil (Table 3), however, reser-
pine was less effective in potentiating antibiotic 
susceptibility other than the quinolones (ofloxacin 
and norfloxacin) and gentamicin. In addition to 
that, reserpine had no effect at all on the activity 
of ß-lactams on MRSA (Table 3) this effect was 
substantiated by its diminished ability to influence 
accumulation of EtBr (Figure 1, 2). The inhibition of 
efflux pumps by reserpine is dependent on the type 
and nature of the substrate [14]. Pumps like NorA, 
QacA, NorM of MRSA are known to be inhibited by 
reserpine but not by verapamil [20]. Consequently 
another pump must be involved in the resistance 
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to B-lactams here and a suitable candidate seems 
to be the previously suggested AbcA pump. AbcA 
pump is a member of group A family of ATP-de-
pendent transporters which are energized by ATP 
hydrolysis. MgrA is a regulator protein that is a di-
rect activator of the abcA efflux gene in MRSA. 
The deactivation of this regulator protein will result 
in the inhibition of this pump resulting in improved 
susceptibility towards its substrates (quinolones and 
ß-lactams). Moreover the effect of these two MEPIs 
(PSC833 and verapamil) could be simply through 
dissipating the energy of the AbcA pump rendering 
it inactive [21].
This explanation suits well the effect of the lat-
ter two MEPIs since both are P-glycoprotein pump 
inhibitors [22] and exposure of the study strains to 
both of them resulted in a significant difference in 
the diameter of zones of inhibition to the six anti-
biotics (Table 3) and observed difference between 
the level of fluorescence detected after exposure to 
both inhibitors in MRSA (Figure 1). In fact these 
results suggest the possibility of a similar target for 
both Verapamil and PSC833.
ABC transporters are a conserved group of proteins 
that confer not only multidrug resistance in bacteria 
but also resistance to anticancer agents in mamma-
lian cells[23]. PSC833 is therapeutically used at a dose 
of (10 mg/ml/kg). It has been evaluated for safety in 
the clinic and in combination with chemotherapeutic 
agents for cancer therapies [12].We have shown that 
it can act as a bacterial EPI at a concentration of 62.5 
mg/ml and less. One disadvantage of PSC833 is being 
a substrate of the CYP 3A4 cytochrome, which use, 
might result in modified bioavailability and dose of 
other drugs [12]. This disadvantage necessitates more 
in vivo studies to assure its usefulness and safety in 
combination with antibiotics. 
This study showed that PSC833 restored/en-
hanced the activities of several antibiotics on methi-
cillin-resistant S. aureus, suggesting the importance 
of PSC833 as a bacterial efflux inhibitor in vitro. To 
validate the use of PSC833 in combination with ex-
isting antibiotics in treatment of multidrug resistant 
Gram positive bacteria and use in human, synergism 
studies with different antibiotics as well as in vivo 
studies should follow to insure its effectiveness and 
safety.
Conclusions 
The findings in this study indicate that valspodar 
(PSC833) can act as a Gram-positive bacterial efflux 
pump inhibitor at a minimum effective concentra-
tion of 62.5 µg/ml and less depending on type of 
antibiotic. Effect of PSC833 on antibiotic suscepti-
bility was concentration dependent, but not time 
dependent. Our findings showed similarity with 
those of another 1st generation MEPI (verapamil), 
and were significantly (p < 0.05) better than those 
of the natural MEPI (reserpine).  
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